Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites

Journal of Surgical Oncology

Volumn 62, Issue 2, 1996, Pages 128-134

  Jacquet, Pierre ^a   Stuart, O Anthony ^a   Dalton, Rory ^a   Chang, David ^b   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b WESTAT   (United States)

Author keywords

doxorubicin; fibrinolytic therapy; intraperitoneal chemotherapy; tumor implantation; wound

Indexed keywords

ALTEPLASE; ANTINEOPLASTIC AGENT; DOXORUBICIN; FIBRINOLYTIC AGENT;

ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER RECURRENCE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FIBRINOLYTIC THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME; WOUND;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; DOXORUBICIN; INCIDENCE; INJECTIONS, INTRAPERITONEAL; MALE; NEOPLASM SEEDING; NEOPLASMS, EXPERIMENTAL; PERITONEUM; RANDOM ALLOCATION; RATS; RECOMBINANT PROTEINS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0029947080     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199606)62:2<128::AID-JSO9>3.0.CO;2-A     Document Type: Article

References (34)

1. Brukner HW, Stablein DM: Sites of treatment failure: Gastrointestinal Tumor Study Group analyses of gastric, pancreatic, and colorectal trials. Cancer Treat Symp 2:199-210, 1983.
2. Long RTL, Edwards RH: Implantation metastasis as a cause of local recurrence of colorectal carcinoma. Am J Surg 157:194-201, 1989.
3. Griffin JF, Smalley SR, Jewell W, Paradelo JC, et al.: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66:56-61, 1990.
4. Murthy MS, Goldschmidt RA, Rao LN, Ammirati M, et al.: Influence of surgical trauma on experimental metastasis. Cancer 64: 2035-2044, 1989.
5. Baker DG, Materson TM, Pace R, Constable WC, Wanebo H: The influence of surgical wound on local tumor recurrence. Surgery 106:525-532, 1989.
6. Weiss L: Some effects of mechanical trauma on the development of primary cancers and their metastases. J Forensic Sciences 35:614-627, 1990.
7. Speyer JL: The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 12(Suppl 4):23-28, 1985.
8. Cunliffe WJ, Sugarbaker PH: Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 76:1082-1090, 1989.
9. Myers CE, Collins JM: Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1:395-407, 1983.
10. Yu W, Sugarbaker PH, Whang I: Randomized controlled trial of early postoperative intraperitoneal chemotherapy in gastric cancer: A preliminary report. Reg Cancer Treat 2:90-93, 1994.
11. Sautner T, Hofbauer F, Despich D, Sciessel R, Jackesz R: Adjuvant intraperitoneal chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12:970-974, 1994.
12. Sugarbaker PH: Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer. World J Surg 19:235-240, 1995.
13. Jacquet P, Sugarbaker PH: Influence of wound healing on gastrointestinal cancer recurrence. Wounds 7:40-47, 1995.
14. Murthy MS, Scanlon EF, Silverman RH, Goodheart R, et al.: The role of fibronectin in tumor implantation at surgical sites. Clin Exp Metast 11:159-173, 1993.
15. Murthy MS, Summaria LJ, Miller RJ, Wyse TB, Goldschmidt RA, Scanlon EF: Inhibition of tumor implantation at sites of trauma by plasminogen activator. Cancer 68:1724-1730, 1991.
16. Martin MS, Martin R, Michiels R, Bastien H, et al.: An experimental model for cancer of the colon and rectum. Digestion 8:22-34, 1973.
17. Houston KA, McRitchie DI, Rotstein OD: Tissue plasminogen activator reverses the deleterious effect of infection on colonic wound healing. Ann Surg 211:130-135, 1990.
18. van Goor H, de Graaf JS, Kooi K, Sluiter WJ, Bom VJ, van der Meer J, Bleichrodt RP: Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis. J Am Coll Surg 179:407-411, 1994.
19. Schabel FM: Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40:558-568, 1977.
20. Shapiro DM, Fugmann RA: A role for chemotherapy as an adjunct to surgery. Cancer Res 17:1098-1101, 1957.
21. Griswold DP: The potential for murine tumor models in surgical adjuvant chemotherapy. Cancer Chemother Rep 5:187-204, 1975.
22. Martin DS, Fugmann RA, Hayworth P: Surgery, cancer chemotherapy, host defenses, and tumor size. J Natl Cancer Inst 29:817-834, 1962.
23. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39:3861-3865, 1979.
24. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488-1492, 1983.
25. Baigne RJ, Lamont PM, Kwiatlkowski D, Dallman MJ, Morris PJ: Systemic cytokine response after major surgery. Br J Surg 79:757-760, 1992.
26. Tsukada K, Katoh H, Suzuki T, Takenoshita S, Nagamashi Y: Correlations of peritoneal interleukin-6, serum beta-2 microglobulin and urinary beta-2 microglobulin after elective abdominal surgery. APMIS 101:409-412, 1993.
27. Dong Z, Radinsky R, Dominic F, Tsan R, Bucana CD, Wilmanns C, Fidler IJ: Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 86:913-920, 1994.
28. Schluesener HJ: Transforming growth factors type B inhibit multidrug transport in rat astrocyte cell lines. Autoimmunity 9:269-275, 1991.
29. Moulton TA, Jiang H, Guarini L, Fetell MR, Fisher PB: Induction of growth suppression and modification of gene expression in multidrug resistance human glioblastoma multiforme cells by recombinant human fibroblast and immune interferon. Int J Cancer 51:373-378, 1992.
30. diZerega GS, Rodgers KE: Peritoneum. In diZerega GS, Rodgers KE (eds): "The Peritonem." New York: Springer-Verlag, 1992, pp 2-22.
31. Yamamoto K, Murae M, Yasuda M: RGD-containing peptides inhibit experimental peritoneal seeding of human ovarian cancer cells. Acta Obstet Gynaecol Jpn 43:1687-1692, 1991.
32. See WA, Chapman PH: Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. J Urol 138:182, 1987.
33. Gunji Y, Gorelik E: Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 48:5216-5221, 1988.
34. Chesebro JHG, Knatterud G, Braunwald E: Thrombolytic therapy. N Engl J Med 319:1544-1545, 1988.